Skip to content
Delayed ~15 min

KPTI KARYOPHARM THERAPEUTICS

Permanent stock page ↗

Health Care · Russell 2000

Next earnings: Thu 12 Nov 2026 · estimated

What 10 analyst firms say about KARYOPHARM THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works

0.05 USD−0.01 (−8.65%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+19,329.3%to the avg target 10.67 USD+10.61 USD
Buy 5 · Hold 2 · Sell 0

7 rated views · 10 analyst/firm records · 10 firms

Latest report31 Jul 2026avg report date 31 May
Target rangePrice is below every target

Radar score

  • Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
  • Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD

Recent analyst activity · last 90 days

Our tracked history has 2 reports on KPTI from 2 analyst firms in the last 90 days (10 firms in the past year).

Ratings, latest available report against the previous one: 0 upgrades and 1 downgrade.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
BairdMichael UlzHold31 Jul 20263.00 USD
Cantor FitzgeraldYanni SouroutzidisBuy9 Jun 2026—
Goldman SachsUnnamed analyst—17 Dec 202512.00 USD
H.C. WainwrightRobert BurnsConflictConflicting reports · excluded31 Jul 20263.00 USD
JefferiesMaury RaycroftBuy31 Jul 202611.00 USD
Piper SandlerEdward TenthoffBuy31 Jul 20267.00 USD
RBC Capital MarketsBrian AbrahamsBuy21 Jul 2026Conflicting reports · excluded
Rodman & RenshawMichael G KingBuy31 Jul 202628.00 USD · 10 Mar 2026
Weiss RatingsUnnamed analyst—24 Sep 2026—
Data feed RESEARCHResearch TeamHold15 Jun 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 08:11 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.